CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Biotechnology

Healthcare
$4.00 +2.42%

+$0.10 today

Market cap
$251.02M
Beta
0.08
P/E (TTM)
-2.8
EPS (TTM)
-$1.49
52W Low $1.31High $7.75

Volume 0.21M

Average 0.10M

Big Five Numbers

CAMP4 Therapeutics Corporation growth analysis

Start with the long-run numbers that show whether CAMP compounds: return on capital and growth in sales, earnings, equity, and free cash flow.

Big Five Numbers

CAGR by period · ROIC shows average

Metric 10yr 5yr3yr1yr
EPS
N/AN/AN/AN/A
Revenue
N/AN/AN/A+436.5%
Equity
N/AN/AN/A-51.5%
Cash
N/AN/A+9.6%+71.0%
ROIC
N/A-55.9%-76.0%-50.8%

Analysis

Latest growth is strongest in Revenue at +436.5% and weakest in Equity at -51.5%. Three-year average ROIC is -76.0%, which helps show whether that growth is being earned efficiently.

Growth analysis

Is growth accelerating or fading?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/AN/A
+35.4% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Forward estimates point to Revenue at +35.4% (5yr), giving you a quick read on expected growth from here.

Revenue segments

Where does the growth come from?

Break revenue down by product and geography to see which parts of the business drive the trend.

Revenue by segment

Where CAMP earns its revenue, as reported in company filings

  • Product
  • Application Subscriptions And Other Services
  • Wireless Datacom
  • Telematics Systems
  • Telematics Products
  • Application Subscriptions And Related Products And Other Services
  • Other
Revenue by segment for FY2022
Segment · FY2022 Revenue Share YoY
Product$188.88M64.0%+3.3%
Application Subscriptions And Other Services$106.07M36.0%-6.1%

Figures in USD. Smaller segments are grouped as "Other".

Free cash flow

Does growth turn into cash?

Check whether reported growth converts into free cash flow after capital spending.

Free Cash Flow

Net Income to FCF bridge

Cash Flow Statement

FY2025

= Net Income-$80.4M
+ D&A$1.6M
+ Stock-Based Comp$4.0M
+ Deferred Tax$0
+ Working Capital$13.0M
+ Other Non-Cash$32.2M
= Operating Cash Flow-$29.6M
- Capex-$279.0K
= Free Cash Flow-$29.8M

Analysis

FY2025 free cash flow is -$29.8M. FCF conversion is 37.1% of net income. Operating cash flow was -$29.6M, with capex of -$279.0K. The largest bridge item is Other Non-Cash at $32.2M.

Price targets

What do analysts expect from the price?

Compare the current price with the low, average, and high analyst targets.

Wall Street price targets

1-year price history with analyst consensus target

Growth

Unlock analyst target range

Sign in free to see low, average, high targets and implied upside for CAMP.

Sign in free

Analyst ratings

How do analysts rate the stock?

Review the buy, hold, and sell split and recent upgrades and downgrades.

Analyst ratings

Buy, hold, and sell recommendations and recent rating changes

Unlock analyst ratings

Sign in free to see the buy/hold/sell breakdown and recent rating changes for CAMP.

Sign in free

Competitor growth

How does CAMP4 Therapeutics Corporation grow against peers?

Compare historical and forecast growth with similar companies.

Competitor Growth

Peer CAGR comparison & forward estimates

CompanyMarket Cap10yr5yr3yrFwd

ALX Oncology Holdings Inc.

ALXO

$143.81M———
—2 analysts

Unicycive Therapeutics, Inc.

UNCY

$97.25M———
—5 analysts

Vaxart, Inc.

VXRT

$90.17M+38.3%+125.8%+1204.0%
-10.6% (4yr)1 analysts

PMV Pharmaceuticals, Inc.

PMVP

$67.73M———
—1 analysts

Acrivon Therapeutics, Inc. Common Stock

ACRV

$62.14M———
—2 analysts

MindWalk Holdings Corp.

HYFT

$47.10M—+10.7%+8.2%
+9.4% (6yr)1 analysts

Biomea Fusion, Inc.

BMEA

$42.31M———
—3 analysts

aTyr Pharma, Inc.

ATYR

$14.97M—-55.1%-73.7%
+293.4% (5yr)5 analysts

Questions

Growth questions

Common questions about CAMP's growth, answered from reported and forecast figures.

Is CAMP growing revenue?

Revenue grew 436.5% year over year, from $652,000.00 to $3.50M.

Is CAMP turning growth into profit?

The latest net margin is -2298.5%, which shows how much revenue became net income.